This page is intended for medical institution personnel who refer patients to our hospital.

Kitano Hospital has begun providing obesity treatment using semaglutide (Ugovi® subcutaneous injection) and tirzepatide (Zepbound® subcutaneous injection), which are now indicated for obesity. As there are various conditions for treatment, please refer to the following when making a referral.

Ugobi® Registered Trademark No. 6482782
ZepBound® Registered Trademark No. 6823693

Those who are eligible for treatment with the drug

This applies to those who meet both 1 and 2.

1. Those who have been diagnosed with one or more of the following: hypertension, dyslipidemia, or type 2 diabetes, and are receiving drug treatment for any of these, and have been following an appropriate diet and exercise regimen for at least six months.
2. BMI 35kg/㎡ or more or 27kg/㎡ or moreTwo or more obesity-related health problems^*Those who have

Conditions for starting "Ugobi" and "Zep Bound"

• Before starting treatment, patients will receive medical treatment, nutritional guidance, and exercise therapy at our hospital for six months.
• Even after starting, nutritional guidance is required at least once every two months
• Treatment duration is up to 68 to 72 weeks

Precautions when referring patients

• We may reassess your suitability after examining you at our hospital.
• In accordance with the Ministry of Health, Labor and Welfare's "Guidelines for Promoting Optimal Use," patients are required to receive six months of nutritional guidance at our hospital before using the medication.

*We would appreciate it if doctors could inform their patients of the above points in advance.

inquiry